Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 5 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A
2(50.0%)
Phase 1
2(50.0%)
4Total
N/A(2)
Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01475760Not ApplicableCompleted

A Study to Evaluate Chitosan Chewing Gum in Patients With Chronic Kidney Disease

Role: collaborator

NCT01319578Not ApplicableCompleted

PD Study to Assess Phosphate Binding Characteristics of K2CG Chewing Gum

Role: collaborator

NCT01402648Phase 1Completed

Estrogen Receptor Beta Agonists (Eviendep) and Polyp Recurrence

Role: lead

NCT01311973Completed

Salivary Phosphorus and Level of Kidney Function

Role: collaborator

NCT01057108Phase 1Completed

Double Blind Randomized Placebo Controlled Trial of FOSTRAP Chewing Gum in Patients With CKD and Hyperphosphatemia

Role: collaborator

All 5 trials loaded